RAPS launched global compensation survey of regulatory professionals

Published: 24-May-2018
Media Pharmaceutical

A comprehensive survey of regulatory professionals’ compensation, education, professional experience, demographics and work responsibilities


RAPS has launched its biennial survey of healthcare product regulatory professionals around the world, the Global Compensation and Scope of Practice Survey.

According to RAPS, it is the most comprehensive survey of regulatory professionals’ compensation, education, professional experience, demographics and work responsibilities.

The survey was open to anyone involved in healthcare product regulation or compliance, including those working in industry, government, law, research, consulting or any other relevant areas. The 2018 survey closed 18 May.

“RAPS has been conducting this research for more than 20 years, and it has been invaluable in improving understanding of the regulatory profession and its evolution,” said RAPS Executive Director Paul Brooks.

“It also yields extremely useful compensation data, giving individuals, regulatory employers, recruiters and other stakeholders insight into regulatory professionals’ compensation, trends and the factors that most directly influence compensation. This year, we are able to offer participants even greater value by providing them with a personal profile they can use to benchmark themselves against the aggregated survey results.”

The results of the 2018 survey are expected to be released in August.

  • Companies:
  • RAPS Regulatory Affairs Professionals Society
See more

You may also like

Regulatory

Waiting in the shadow of a no deal Brexit

Read more
Pharmaceutical companies still do not know how they will be impacted by Brexit after Prime Minister Theresa May decided to postpone a vote on her deal with the European Union (EU), writes Paul Brooks, Executive Director, RAPS

Trending Articles

  1. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  2. Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01 The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  4. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
  5. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

Waiting in the shadow of a no deal Brexit

Pharmaceutical companies still do not know how they will be impacted by Brexit after Prime Minister Theresa May decided to postpone a vote on her deal with the European Union (EU), writes Paul Brooks, Executive Director, RAPS
Regulatory

Brexit and healthcare product regulation

Navigating the grey
Regulatory

Brexit: minimising the unexpected

Paul Brooks, Executive Director, RAPS, comments on Brexit and the operational trade and regulatory environment affecting the UK's pharmaceutical and medical device sectors
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
Distribution

Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01

The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
Regulatory

Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy

The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
Manufacturing

Novo Nordisk invests DKK 8.5bn into new Danish modular production site

This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
Subscribe now